GET DAILY SIGNALSImmunic (IMUX): Analyst Targets Point to Potential +350% Upside
Key Takeaways
- The central target of $35 is the arithmetic mean of the verified analyst price targets reviewed, with a wide range from approximately $19 to $70 (some data providers list a high near $85).
- At a recent price near $7.80, reaching $35 implies upside of roughly 350% — a very large move that is multiples above even the stock's 52-week high of $17.43.
- Immunic's lead drug, vidofludimus calcium (IMU-838), is in Phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026 — a binary catalyst that drives the wide target range.
- The company's balance sheet is a key support: with roughly $155 million in cash versus a ~$106 million market capitalization, the enterprise value is effectively negative.
- The biggest risks are clinical failure, further dilution, and a 1-for-10 reverse stock split completed in April 2026 that has left the shares trading below key moving averages.
- For more detail, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
Breaking Down the Analyst Consensus
Wall Street coverage of IMUX is overwhelmingly bullish, though targets span an unusually wide band because the shares are effectively an option on a single Phase 3 readout. Reviewing recent, individually attributable targets — Wedbush (Martin Fan) at $45, H.C. Wainwright at $22, Stifel Nicolaus at $25, B. Riley (William Wood) at $27, Roth Capital at $29, and a $70 initiation that traces to coverage begun in March 2026 — the calculated mean lands near $35, with the full range running from roughly $19 to $70. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Different trackers quote slightly different consensus figures (from about $35 to $43) because the company completed a 1-for-10 reverse stock split in April 2026 and providers do not always reconcile pre- and post-split targets identically. The low-end targets around $19 to $22 reflect cautious views that the stock already embeds meaningful downside protection from its cash position, while the $70-plus targets reflect an assumption that Phase 3 data meaningfully de-risks the lead program. None of these figures should be read as a guarantee of future performance.
Current Market Position and Path Toward the Target
With the shares near $7.80, reaching $35 would require a rise of roughly 350% — a very large move, not a near-term technical objective. For context, the stock's 52-week range is $5.06 to $17.43, so even fully retracing to its prior high would leave it less than halfway to the target. The path to $35 therefore hinges almost entirely on binary clinical outcomes and the subsequent reassessment of the pipeline's value, rather than on gradual fundamental improvement. Immunic currently generates no product revenue and posts a trailing EPS (earnings per share) loss of about $3.83.
What Could Support a Move Toward the Target
The strongest support is the balance sheet and the catalyst calendar. Immunic reported roughly $155 million in cash at its most recent quarter, against a market capitalization near $106 million, leaving a negative enterprise value — the market is assigning little to no credit to the pipeline. A February 2026 financing of about $200 million removed near-term capital concerns, according to B. Riley, which described current levels as a "compelling entry point." Positive top-line data from the Phase 3 relapsing multiple sclerosis program, expected by the end of 2026, is the central event that could justify a re-rating. The lead molecule combines a first-in-class Nurr1-activating mechanism with DHODH inhibition, and analysts such as Roth Capital have raised targets (to $29 from $19) ahead of the readout.
What Could Prevent the Target From Being Reached
The principal risk is clinical failure or inconclusive data, which could sharply compress the valuation of a company with no approved products. Even in a success scenario, reaching $35 would require not only a positive readout but also a successful path to regulatory filing and ultimately commercialization — a multi-step process with execution risk. Additional risks include future equity raises that dilute existing holders, the April 2026 reverse stock split's impact on sentiment, and the competitive multiple sclerosis landscape. The stock also carries a beta near 1.5, making it more volatile than the broader market.
Technical Levels and Market Structure
Technically, the shares sit below their 50-day moving average near $8.93 and their 200-day moving average near $11.55, reflecting persistent selling pressure since the spring. The 52-week low of $5.06 acts as a nearby support level, while $11.50 to $12.00 and the 52-week high of $17.43 represent the primary resistance levels. Because $35 sits far above all observable chart-based resistance, the target is best understood as a fundamental, event-driven objective rather than a technical milestone. From what I see, this setup makes the clinical catalyst even more decisive.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though the reported figures here are best interpreted as event-driven views rather than steady forecasts. The single most important upcoming item is the top-line data from the Phase 3 relapsing multiple sclerosis trial, expected by the end of 2026. Investors should also watch the company's quarterly cash balance and operating burn, any further analyst target revisions around the readout, updates on the IMU-856 Phase 2 program, and any new financing announcements. I’m watching this closely as the data approaches.
Exploring AI Tools for Dynamic Analysis
In my own research process, I’ve turned to Tickeron’s AI Daily Buy/Sell Signals to get a more dynamic view on names like IMUX. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. It helps me discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone, serving as one input alongside my own review of the clinical catalyst calendar.
Final Assessment
The $35 central target is the arithmetic mean of current analyst price targets and reflects a genuinely binary setup: Immunic's roughly $155 million cash position supports the shares near current levels, while the pending Phase 3 multiple sclerosis readout is what would need to justify a move toward $35 — a roughly 350% gain far beyond the stock's 52-week high. Supportive factors include the negative enterprise value, the reduced capital overhang, and a "Strong Buy" leaning consensus, while the dominant obstacles are clinical risk, dilution, and the wide disagreement among analysts (roughly $19 to $70). The outcome will be decided less by near-term trading than by the quality of the trial data and the company's ability to fund and execute the path to commercialization.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for IMUX turns positive, indicating new upward trend
IMUX saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned positive. In 76 of the 81 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMUX's RSI Oscillator exited the oversold zone, 27 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for IMUX just turned positive on October 15, 2026. Looking at past instances where IMUX's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
Following a +2.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMUX advanced for three days, in 212 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 50-day moving average for IMUX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMUX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for IMUX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.829) is normal, around the industry mean (3.498). P/E Ratio (-2.183) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. IMUX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMUX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceuticals and oral therapies for the treatment of chronic inflammatory and autoimmune diseases
Industry Biotechnology
Advertisement